Glioblastoma is a devastating disease with a survival that is measured in months. The recent FDA approval of the Optune device for the treatment of newly-diagnosed glioblastoma was a paradigm shift in the field of neuro-oncology. We will focus our discussion on the biological underpinnings of this device and clinical data supporting its use.